{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:18:08Z","timestamp":1790914688639,"version":"4.1.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>According to the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, myelodysplastic\/myeloproliferative neoplasms are clonal myeloid neoplasms that have some clinical, laboratory, or morphologic findings that support a diagnosis of myelodysplastic syndrome, and other findings that are more consistent with myeloproliferative neoplasms. These disorders include chronic myelomonocytic leukemia, atypical chronic myeloid leukemia (BCR-ABL1 negative), juvenile myelomonocytic leukemia, and myelodysplastic\/myeloproliferative neoplasms, unclassifiable. The best characterized of these latter unclassifiable conditions is the provisional entity defined as refractory anemia with ring sideroblasts associated with marked thrombocytosis. This article focuses on myelodysplastic\/myeloproliferative neoplasms of adulthood, with particular emphasis on chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts associated with marked thrombocytosis. Recent studies have partly clarified the molecular basis of these disorders, laying the groundwork for the development of molecular diagnostic and prognostic tools. It is hoped that these advances will soon translate into improved therapeutic approaches.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.264","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T20:33:13Z","timestamp":1323289993000},"page":"264-272","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Myelodysplastic\/Myeloproliferative Neoplasms"],"prefix":"10.1182","volume":"2011","author":[{"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosangela","family":"Invernizzi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Pavia Medical School and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111720143582500_B1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"key":"2019111720143582500_B2","first-page":"85","article-title":"Myelodysplastic\/myeloproliferative neoplasms, unclassifiable","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Vardiman","year":"2008"},{"issue":"1","key":"2019111720143582500_B3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/asheducation-2010.1.357","article-title":"Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia","volume":"2010","author":"Loh","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2019111720143582500_B4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/leu.2008.119","article-title":"The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"key":"2019111720143582500_B5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/asheducation-2011.1.250","article-title":"Evaluation, classification and genetics in the diagnosis of myeloproliferative neoplasm (MPN) variants","volume":"2011","author":"Vardiman","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2019111720143582500_B6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3324\/haematol.2008.005421","article-title":"Morphological evaluation of monocytes and their precursors","volume":"94","author":"Goasguen","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"2019111720143582500_B7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"2019111720143582500_B8","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.3324\/haematol.2009.014001","article-title":"Molecular basis of myelodysplastic\/myeloproliferative neoplasms","volume":"94","author":"Reiter","year":"2009","journal-title":"Haematologica"},{"issue":"25","key":"2019111720143582500_B9","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2009-02-205690","article-title":"Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms","volume":"113","author":"Jankowska","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111720143582500_B10","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","article-title":"TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia","volume":"94","author":"Kosmider","year":"2009","journal-title":"Haematologica"},{"issue":"24","key":"2019111720143582500_B11","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111720143582500_B12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111720143582500_B13","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111720143582500_B14","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111720143582500_B15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"7257","key":"2019111720143582500_B16","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"issue":"24","key":"2019111720143582500_B17","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","article-title":"250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies","volume":"68","author":"Dunbar","year":"2008","journal-title":"Cancer Res"},{"issue":"7","key":"2019111720143582500_B18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"2019111720143582500_B19","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"2019111720143582500_B20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"7325","key":"2019111720143582500_B21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"issue":"6","key":"2019111720143582500_B22","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1172\/JCI45213","article-title":"Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia","volume":"121","author":"Aucagne","year":"2011","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111720143582500_B23","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"3","key":"2019111720143582500_B24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2019111720143582500_B25","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"7","key":"2019111720143582500_B26","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3324\/haematol.11051","article-title":"Chronic myelomonocytic leukemia in the light of the WHO proposals","volume":"92","author":"Germing","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"2019111720143582500_B27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111720143582500_B28","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"issue":"18","key":"2019111720143582500_B29","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111720143582500_B30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"issue":"7","key":"2019111720143582500_B31","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"issue":"2","key":"2019111720143582500_B32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2011.08631.x","article-title":"Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia","volume":"153","author":"Bacher","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111720143582500_B33","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111720143582500_B34","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia","volume":"95","author":"Onida","year":"2002","journal-title":"Cancer"},{"issue":"11","key":"2019111720143582500_B35","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"2019111720143582500_B36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2141.1988.tb02433.x","article-title":"The syndrome of abnormal chromatin clumping in leucocytes: a myelodysplastic disorder with proliferative features?","volume":"70","author":"Felman","year":"1988","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111720143582500_B37","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"issue":"48","key":"2019111720143582500_B38","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1038\/sj.onc.1208850","article-title":"The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene","volume":"24","author":"Bousquet","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"2019111720143582500_B39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14728222.2011.538683","article-title":"PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms","volume":"15","author":"Hoeller","year":"2011","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"2019111720143582500_B40","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"key":"2019111720143582500_B41","first-page":"721","article-title":"Sideroblastic anemias","volume-title":"Clinical Hematology","author":"Cazzola","year":"2005"},{"issue":"6","key":"2019111720143582500_B42","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3324\/haematol.2011.044628","article-title":"Ring sideroblasts and sideroblastic anemias","volume":"96","author":"Cazzola","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"2019111720143582500_B43","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3324\/haematol.13405","article-title":"Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts","volume":"93","author":"Mufti","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"2019111720143582500_B44","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood-2002-07-2006","article-title":"Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia","volume":"101","author":"Cazzola","year":"2003","journal-title":"Blood"},{"key":"2019111720143582500_B45","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria. A basis for clinical decision-making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111720143582500_B46","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood-2005-12-4769","article-title":"Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype","volume":"108","author":"Pellagatti","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111720143582500_B47","doi-asserted-by":"crossref","first-page":"e1970","DOI":"10.1371\/journal.pone.0001970","article-title":"The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts","volume":"3","author":"Boultwood","year":"2008","journal-title":"PLoS One"},{"issue":"6","key":"2019111720143582500_B48","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1365-2141.2010.08174.x","article-title":"Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF","volume":"149","author":"Nikpour","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111720143582500_B49","article-title":"Somatic mutation of SF3B1 in myelodysplasia with ring sideroblasts","author":"Papaemmanuil","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111720143582500_B50","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111720143582500_B51","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3324\/haematol.2009.013631","article-title":"Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis","volume":"95","author":"Flach","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"2019111720143582500_B52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3324\/haematol.11374","article-title":"Myelodysplastic\/myeloproliferative disorders","volume":"93","author":"Malcovati","year":"2008","journal-title":"Haematologica"},{"issue":"21","key":"2019111720143582500_B53","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood.V116.21.1862.1862","article-title":"Mutation analysis of TET2 reveals the clonal nature of refractory anemia with ring sideroblasts [Abstract]","volume":"116","author":"Malcovati","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111720143582500_B54","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2141.2005.05747.x","article-title":"Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic\/myeloproliferative disease of older adults","volume":"131","author":"Shaw","year":"2005","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111720143582500_B55","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood.V116.21.4113.4113","article-title":"Outcome of refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) in a large cohort of patients [Abstract]","volume":"116","author":"Girodon","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111720143582500_B56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2010-01-263087","article-title":"Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis","volume":"116","author":"Huls","year":"2010","journal-title":"Blood"},{"key":"2019111720143582500_B57","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia [published online ahead of print September 11, 2011]","author":"Yoshida","journal-title":"Nature"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/264\/1492877\/bep00111000264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/264\/1492877\/bep00111000264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T13:24:07Z","timestamp":1713187447000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/264\/96975\/MyelodysplasticMyeloproliferative-Neoplasms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.264","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}